Under the terms of their agreement, the companies plan to leverage expertise, to create highly efficient and effective product flow. Initially, they will focus on a generic oncology product which has been developed, but further collaboration will include all aspects of drug development from active pharmaceutical ingredients (APIs) manufacturing through to regulatory approval and distribution.

Oncogen will primarily focus on product development, filing the abbreviated new drug applications (ANDAs) for US Food and Drug Administration approval and the commercial launch of the products in the US market. Manufacturing will be carried out at their facility in Malaysia and products should be ready for initial shipments by the middle of 2022

BrightGene recently announced their successful production of remdesivir, an experimental treatment for coronavirus, however, patents for the drug are currently held by the American company Gilead [1].

Related article
Further collaborations formed to penetrate China’s generics market

  
Reference
1. GaBI Online - Generics and Biosimilars Initiative. Chinese company makes copy of patented coronavirus treatment remdesivir [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2021 Sep 10]. Available from: www.gabionline.net/generics/news/Chinese-company-makes-copy-of-patented-coronavirus-treatment-remdesivir

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2021 Pro Pharma Communications International. All Rights Reserved.